We are live on ! Find out more

Xenon Pharmaceuticals

XENE

Market cap $3.64B

37.54 USD

+1.20

3.3%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

37.20

-0.34

0.91%

1 day

3.3%

5 days

2.51%

1 month

0.78%

3 months

-40.51%

6 months

-32.66%

Year to date

-15.62%

1 year

-11.25%

5 years

20.51%

10 years

393.95%

About: Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Employees: 370

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 12.1%

Neutral 63.6%

Negative 24.2%

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

XEN1701 achieved target profile, including desired Na V 1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic cardiovascular effects XEN1120 achieved plasma levels predictive of analgesic effects based on preclinical modeling and was generally well-tolerated New preclinical data in cynomolgus monkeys demonstrated significant reductions in capsaicin-evoked heat pain for Na V 1.7 and K V 7 compounds Phase 2 proof-of-concept studies assessing XEN1701 and XEN1120 in acute pain expected to initiate in H1 2027 VANCOUVER, BC and BOSTON, MA, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced positive Phase 1 study results and new preclinical data supporting the advancement of XEN1701 and XEN1120 to Phase 2 proof-of-concept studies in acute pain. Data were presented in two poster presentations during the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, taking place October 26–30, 2026 in Bangkok, Thailand.

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).

Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

Zacks Investment Research

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP continues to investigate potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).

Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 17,850 share options and 10,500 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of October 1, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

Xenon Pharmaceuticals NASDAQ: XENE said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability.

Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $XENE--XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law.

XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)

Analysts cut price targets and reduced their estimates for azetukalner's psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials -- XENE shares fell as much as 27.6%. NEW YORK, Sept.

Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)

Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate

Azetukalner's focal-seizure application gives Xenon Pharmaceuticals Inc. a potential path to its first commercial revenues, subject to FDA approval. The psychiatry setback weakens expansion potential, but I think epilepsy still provides a viable foundation for the bull case. XENE's liquid balance sheet should help it fund the remaining regulatory work and launch preparations.

Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate

See News Rankings

Price charts implemented using Lightweight Charts™